TFAM is directly regulated by miR-23b in glioma

Jiang,Jiaode; Yang,Jinfu; Wang,Zhifei; Wu,Guangyong; Liu,Fei

doi:10.3892/or.2013.2712

TFAM is directly regulated by miR-23b in glioma

Authors:
- Jiaode Jiang
- Jinfu Yang
- Zhifei Wang
- Guangyong Wu
- Fei Liu
View Affiliations

Affiliations: Department of Neurosurgery, Third Xiangya Hospital of Central South University, Changsha, Hunan 410013, P.R. China
Published online on: August 30, 2013 https://doi.org/10.3892/or.2013.2712
Pages: 2105-2110

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mitochondrial transcription factor A (TFAM), a high-mobility group (HMG) protein, plays a central role in mitochondrial DNA (mtDNA) replication, transcription and inheritance. It has been shown that TFAM is associated with tumorigenesis. However, little is known regarding the posttranscriptional regulation of TFAM in glioma. In the present study, we found that the protein levels of TFAM were gradually increased, while the expression of miRNA-23b was gradually downregulated with the malignancy of glioma. Luciferase assay data demonstrated that miRNA-23b directly regulated TFAM. Furthermore, forced overexpression of miRNA-23b in U251 cells markedly inhibited the proliferation, cell cycle progression, migration and colony formation, while overexpression of TFAM significantly enhanced these biological processes. We further examined the related molecular mechanism, and found that the activity of the PI3K/Akt signaling pathway, critical for cell proliferation and migration, was suppressed in miRNA-23b-overexpressing U251 cells but was upregulated in TFAM-overexpressing cells. In addition, the expression levels of invasion-related MMP2 and MMP9 were decreased in miRNA-23b-overexpressing U251 cells but were increased in TFAM-overexpressing cells. Taken together, the present study provides a new regulatory mechanism as well as a promising therapy target for glioma.

View Figures

View References

1	Goodenberger ML and Jenkins RB: Genetics of adult glioma. Cancer Genet. 205:613–621. 2012. View Article : Google Scholar : PubMed/NCBI
2	Surawicz TS, Davis F, Freels S, Laws ER Jr and Menck HR: Brain tumor survival: results from the National Cancer Data Base. J Neurooncol. 40:151–160. 1998. View Article : Google Scholar : PubMed/NCBI
3	Bondy ML, Scheurer ME, Malmer B, et al: Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer. 113:1953–1968. 2008. View Article : Google Scholar : PubMed/NCBI
4	Chargari C, Moncharmont C, Levy A, et al: Cancer stem cells, cornerstone of radioresistance and perspectives for radiosensitization: glioblastoma as an example. Bull Cancer. 99:1153–1160. 2012.(In French).
5	Warda M, Kim HK, Kim N, Ko KS, Rhee BD and Han J: A matter of life, death and diseases: mitochondria from a proteomic perspective. Expert Rev Proteomics. 10:97–111. 2013. View Article : Google Scholar : PubMed/NCBI
6	Uchiumi T and Kang D: The role of TFAM-associated proteins in mitochondrial RNA metabolism. Biochim Biophys Acta. 1820:565–570. 2012. View Article : Google Scholar : PubMed/NCBI
7	Cheng Z and Ristow M: Mitochondria and metabolic homeostasis. Antioxid Redox Signal. Mar 28–2013.(Epub ahead of print).
8	Li X, Zhang G, Luo F, et al: Identification of aberrantly expressed miRNAs in rectal cancer. Oncol Rep. 28:77–84. 2012.PubMed/NCBI
9	Ambros V: The functions of animal microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
10	Nikaki A, Piperi C and Papavassiliou AG: Role of microRNAs in gliomagenesis: targeting miRNAs in glioblastoma multiforme therapy. Expert Opin Investig Drugs. 21:1475–1488. 2012. View Article : Google Scholar : PubMed/NCBI
11	Phang JM and Liu W: Proline metabolism and cancer. Front Biosci. 17:1835–1845. 2012. View Article : Google Scholar
12	Jin L, Wessely O, Marcusson E, Ivan C, Calin G and Alahari SK: Pro-oncogenic factors miR-23b and miR-27b are regulated by Her2/Neu, EGF, and TNFα in breast cancer. Cancer Res. 73:2884–2889. 2013.PubMed/NCBI
13	Yoshida T, Azuma H, Aihara K, et al: Vascular smooth muscle cell proliferation is dependent upon upregulation of mitochondrial transcription factor A (mtTFA) expression in injured rat carotid artery. Atherosclerosis. 178:39–47. 2005. View Article : Google Scholar : PubMed/NCBI
14	Kim AJ, Jee HJ, Song N, Kim M, Jeong SY and Yun J: p21^WAF1/C1P1 deficiency induces mitochondrial dysfunction in HCT116 colon cancer cells. Biochem Biophys Res Commun. 430:653–658. 2013.PubMed/NCBI
15	Han B, Izumi H, Yasuniwa Y, et al: Human mitochondrial transcription factor A functions in both nuclei and mitochondria and regulates cancer cell growth. Biochem Biophys Res Commun. 408:45–51. 2011. View Article : Google Scholar : PubMed/NCBI
16	Guo J, Zheng L, Liu W, et al: Frequent truncating mutation of TFAM induces mitochondrial DNA depletion and apoptotic resistance in microsatellite-unstable colorectal cancer. Cancer Res. 71:2978–2987. 2011. View Article : Google Scholar : PubMed/NCBI
17	Ishteiwy RA, Ward TM, Dykxhoorn DM and Burnstein KL: The microRNA -23b/-27b cluster suppresses the metastatic phenotype of castration-resistant prostate cancer cells. PLoS One. 7:e521062012. View Article : Google Scholar : PubMed/NCBI
18	Zaman MS, Thamminana S, Shahryari V, et al: Inhibition of PTEN gene expression by oncogenic miR-23b-3p in renal cancer. PLoS One. 7:e502032012. View Article : Google Scholar : PubMed/NCBI
19	Geng J, Luo H, Pu Y, et al: Methylation mediated silencing of miR-23b expression and its role in glioma stem cells. Neurosci Lett. 528:185–189. 2012. View Article : Google Scholar : PubMed/NCBI
20	Loftus JC, Ross JT, Paquette KM, et al: miRNA expression profiling in migrating glioblastoma cells: regulation of cell migration and invasion by miR-23b via targeting of Pyk2. PLoS One. 7:e398182012. View Article : Google Scholar : PubMed/NCBI
21	Chen L, Han L, Zhang K, et al: VHL regulates the effects of miR-23b on glioma survival and invasion via suppression of HIF-1α/VEGF and β-catenin/Tcf-4 signaling. Neuro Oncol. 14:1026–1036. 2012.PubMed/NCBI
22	Berg M and Soreide K: EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy. Discov Med. 14:207–214. 2012.PubMed/NCBI
23	Papadimitrakopoulou V: Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer. J Thorac Oncol. 7:1315–1326. 2012. View Article : Google Scholar : PubMed/NCBI
24	De Luca A, Maiello MR, D’Alessio A, Pergameno M and Normanno N: The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets. 16(Suppl 2): S17–S27. 2012.PubMed/NCBI
25	Rietz A and Spiers J: The relationship between the MMP system, adrenoceptors and phosphoprotein phosphatases. Br J Pharmacol. 166:1225–1243. 2012. View Article : Google Scholar : PubMed/NCBI
26	Bauvois B: New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochim Biophys Acta. 1825:29–36. 2012.PubMed/NCBI